Ravulizumab: meta-analysis of COVID-19 studies

0 0.5 1 1.5+ All studies -5% 2 481 Improvement, Studies, Patients Relative Risk Mortality -5% 2 481 RCTs -5% 2 481 RCT mortality -5% 2 481 Late -5% 2 481 Ravulizumab for COVID-19 c19early.org December 2025 Favorsravulizumab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ALXN1210-COV-305 Annane (RCT) -8% 1.08 [0.74-1.56] death 55/135 25/66 Ventilated patients Improvement, RR [CI] Treatment Control TACTIC-R Hall (RCT) 1% 0.99 [0.52-1.87] death 135 (n) 145 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Late treatment -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk All studies -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk 2 ravulizumab COVID-19 studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Effect extraction pre-specified(most serious outcome) Favors ravulizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ALXN1210-COV-305 Annane (RCT) -8% 1.08 [0.74-1.56] 55/135 25/66 Ventilated patients Improvement, RR [CI] Treatment Control TACTIC-R Hall (RCT) 1% 0.99 [0.52-1.87] 135 (n) 145 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Late treatment -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk All studies -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk 2 ravulizumab COVID-19 mortality results c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Favors ravulizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ALXN1210-COV-305 Annane (RCT) -8% 1.08 [0.74-1.56] death 55/135 25/66 Ventilated patients Improvement, RR [CI] Treatment Control TACTIC-R Hall (RCT) 1% 0.99 [0.52-1.87] death 135 (n) 145 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Late treatment -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk All studies -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk 2 ravulizumab COVID-19 serious outcomes c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Effect extraction pre-specified(most serious outcome) Favors ravulizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ TACTIC-R Hall (RCT) -3% 1.03 [0.76-1.41] no disch. 135 (n) 145 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.86 Late treatment -3% 1.03 [0.76-1.41] 135 (n) 145 (n) 3% higher risk All studies -3% 1.03 [0.76-1.41] 135 (n) 145 (n) 3% higher risk 1 ravulizumab COVID-19 recovery result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.86 Favors ravulizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ALXN1210-COV-305 Annane (RCT) -8% 1.08 [0.74-1.56] death 55/135 25/66 Ventilated patients Improvement, RR [CI] Treatment Control TACTIC-R Hall (RCT) 1% 0.99 [0.52-1.87] death 135 (n) 145 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Late treatment -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk All studies -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk 2 ravulizumab COVID-19 Randomized Controlled Trials c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Effect extraction pre-specified(most serious outcome) Favors ravulizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ALXN1210-COV-305 Annane (RCT) -8% 1.08 [0.74-1.56] 55/135 25/66 Ventilated patients Improvement, RR [CI] Treatment Control TACTIC-R Hall (RCT) 1% 0.99 [0.52-1.87] 135 (n) 145 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Late treatment -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk All studies -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk 2 ravulizumab COVID-19 RCT mortality results c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Favors ravulizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ALXN1210-COV-305 Annane (RCT) -8% 1.08 [0.74-1.56] death 55/135 25/66 Ventilated patients Improvement, RR [CI] Treatment Control TACTIC-R Hall (RCT) 1% 0.99 [0.52-1.87] death 135 (n) 145 (n) Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Late treatment -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk All studies -5% 1.05 [0.76-1.45] 55/270 25/211 5% higher risk 2 ravulizumab COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.76 Effect extraction pre-specified(most serious outcome) Favors ravulizumab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ ALXN1210-COV-305 Annane (RCT) -8% 1.08 [0.74-1.56] death 55/135 25/66 Ventilated patients Improvement, RR [CI] Treatment Control TACTIC-R Hall (RCT) 1% 0.99 [0.52-1.87] death 135 (n) 145 (n) TACTIC-R Hall (RCT) -75% 1.75 [0.71-4.29] death 11/135 7/145 TACTIC-R Hall (RCT) -53% 1.53 [0.88-2.67] progression 135 (n) 145 (n) TACTIC-R Hall (RCT) -24% 1.24 [0.60-2.58] oxygen 135 (n) 145 (n) TACTIC-R Hall (RCT) -3% 1.03 [0.76-1.41] no disch. 135 (n) 145 (n) Ravulizumab COVID-19 outcomes c19early.org December 2025 Favors ravulizumab Favors control